Indian Pharmaceutical Companies and Semaglutide Generics
Indian pharmaceutical companies have increased their manufacturing capabilities in anticipation of the expiration of the semaglutide patent, the molecule in Novo Nordisk’s weight-loss drugs, on March 20.
- India has a reputation for producing cost-effective generic drugs, and this trend is expected to continue with semaglutide.
- Major companies such as Cipla, Sun Pharma, Dr Reddy’s Laboratories, Biocon, Natco, Zydus, and Mankind Pharma are anticipated to release generic versions, potentially reducing prices by 50-70%.
- The patent expiration in Europe and the US, major markets for Indian generics, will occur in 2031, leading to intense domestic competition.
Market Potential and Health Context
The market for semaglutide generics is promising, given India’s health statistics:
- The National Family Health Survey 2019-21 shows 24% of Indian women and 23% of men are overweight.
- There are 77 million Indians with Type 2 diabetes, both considered “lifestyle” diseases.
- The market is projected to grow from $16 million in 2021 to $100 million in 2025, with further growth expected by 2030.
Risks and Quality Concerns
While affordability and accessibility of generics are advantageous, they pose significant risks:
- Quality assurance is a major concern, especially with past scandals involving Indian-manufactured drugs.
- Approximately 28% of drugs in urban India might be counterfeit, with high-value drugs being primary targets.
- Self-medication and over-the-counter access to prescription drugs exacerbate these risks.
Regulation and Supervision
Proper administration of these drugs is crucial:
- They should be taken with a strict diet and exercise regimen under medical supervision.
- Currently, these drugs are being prescribed inappropriately by non-medical professionals.
- Regulatory bodies and the medical community must minimize unhealthy practices to ensure the success of Indian generics domestically and abroad.
